Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
AssigneeAmgen Inc.
InventorsBruce Allen BACH, Florian VOGL
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an Ang2 inhibitor in combination with a taxane.
Claims5
1-11. (canceled)
A method for treating recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in a human patient with ascites by administering (a) 80 mg/m2 of paclitaxel, via i.v., QW (3 weeks on/1 week off);
- and (b) 10 mg/kg 2XCon4(C), via i.v., QW (every week).
A method for treating recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in a human patient with ascites by administering (a) 80 mg/m2 of paclitaxel, via i.v., QW (3 weeks on/1 week off);
- and (b) 3 mg/kg 2XCon4(C), via i.v., QW (every week).
A pharmaceutical composition comprising (a) paclitaxel in an amount suitable for administering to a patient 80 mg/m2, via i.v., QW (3 weeks on/1 week off);
- and (b) 2XCon4(C) in an amount suitable for administering to a patient 10 mg/kg, via i.v., QW (every week).
A pharmaceutical composition comprising (a) paclitaxel in an amount suitable for administering to a patient 80 mg/m2, via i.v., QW (3 weeks on/1 week off);
- and (b) 2XCon4(C) in an amount suitable for administering to a patient 3 mg/kg, via i.v., QW (every week).
Dependencies are inferred from the claim text.